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Abstract
The superoxide dismutase mimetic manganese [III] tetrakis [5,10,15,20]-benzoic acid por-
phyrin (MnTBAP) is a potent antioxidant compound that has been shown to limit weight gain
during short-term high fat feeding without preventing insulin resistance. However, whether
MnTBAP has therapeutic potential to treat pre-existing obesity and insulin resistance
remains unknown. To investigate this, mice were treated with MnTBAP or vehicle during the
last five weeks of a 24-week high fat diet (HFD) regimen. MnTBAP treatment significantly
decreased body weight and reduced white adipose tissue (WAT) mass in mice fed a HFD
and a low fat diet (LFD). The reduction in adiposity was associated with decreased caloric
intake without significantly altering energy expenditure, indicating that MnTBAP decreases
adiposity in part by modulating energy balance. MnTBAP treatment also improved insulin
action in HFD-fed mice, a physiologic response that was associated with increased protein
kinase B (PKB) phosphorylation and expression in muscle and WAT. Since MnTBAP is a
metalloporphyrin molecule, we hypothesized that its ability to promote weight loss and
improve insulin sensitivity was regulated by heme oxygenase-1 (HO-1), in a similar fashion
as cobalt protoporphyrins. Despite MnTBAP treatment increasing HO-1 expression, admin-
istration of the potent HO-1 inhibitor tin mesoporphyrin (SnMP) did not block the ability of
MnTBAP to alter caloric intake, adiposity, or insulin action, suggesting that MnTBAP influ-
ences these metabolic processes independent of HO-1. These data demonstrate that
MnTBAP can ameliorate pre-existing obesity and improve insulin action by reducing caloric
intake and increasing PKB phosphorylation and expression.
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Introduction
Obesity is an increasingly prevalent metabolic disease [1] that is associated with increased risk
of developing type 2 diabetes, a disease that affects approximately 24 million Americans [2]
and costs an estimated $245 billion in total health care costs in the United States [3]. Oxidative
stress and production of reactive oxygen species (ROS) have been linked to the development of
insulin resistance and type 2 diabetes [4], suggesting a potential role for ROS in the pathogene-
sis of these disorders. In support of this notion, augmenting the antioxidant defense system in
mice improves insulin action in the setting of obesity [5–8]. Furthermore, a large observational
study of older adults demonstrated that higher total dietary antioxidant capacity was associated
with improved oral glucose tolerance and insulin action [9]. Despite these associations, it
remains unclear whether antioxidant supplementation or augmentation of the antioxidant
defense system is therapeutically beneficial in the treatment of established metabolic disease
[10,11].
The superoxide dismutases (SOD) are endogenous antioxidants that limit cellular oxidative
damage and improve insulin resistance [5,6]. The cell permeable SOD mimetic, manganese
(III) tetrakis [5,10,15,20] 4-benzoic acid porphyrin (MnTBAP), possesses SOD and catalase
activity [12] and has been shown to reduce oxidative damage [8,13] by quenching both ROS
and reactive nitrogen species [13,14]. However, studies examining the efficacy of MnTBAP on
insulin resistance in rodents have produced conflicting results. Specifically, MnTBAP improves
insulin action in the genetically-obese Lepob/Lepob mouse model [8], yet MnTBAP had no effect
on insulin action in wildtype mice during a short-term HFD regimen, despite protecting mice
from diet-induced weight gain [15]. In addition to the lack of consensus on the effect MnTBAP
on insulin action, it remains unclear whether MnTBAP reduces adiposity in mice with pre-
existing obesity.
We hypothesized that MnTBAP treatment would ameliorate insulin resistance and reduce
adiposity in mice with pre-existing diet-induced obesity. To test this hypothesis, we generated
weight-stable diet-induced obese mice by feeding mice a high-fat diet for five months. Mice
were then treated with MnTBAP or vehicle for five weeks, followed by assessment of insulin
action, energy homeostasis, and adiposity. We found that MnTBAP treatment improved insu-
lin action, in part, by increasing the phosphorylation and total expression of protein kinase B
(PKB), a signaling molecule that is critical to insulin-stimulated glucose transport. We also
observed markedly decreased body weight and fat mass, responses that were associated with
decreased caloric intake and that likely contributed to the enhancement of insulin action.
Because MnTBAP is a metalloporphyrin molecule, we hypothesized that its anti-obesity and
insulin sensitizing actions may be regulated by heme oxygenase-1 (HO-1) [16–19], as had been
shown for cobalt porphyrins [16,18–23]. Although MnTBAP treatment resulted in an up-regu-
lation of HO-1, surprisingly pharmacologic blockade of HO-1 did not attenuate the effects of
MnTBAP on body weight, adiposity, caloric intake or insulin action. Collectively, these find-
ings reveal that MnTBAP reduces adiposity and improves insulin action in part by reducing
caloric intake, a process that appears to be independent of HO-1.
Material and Methods
Animals
Wildtype C57BL6/J male mice (~1 month old) were purchased from the Jackson Laboratory
(Bar Harbor, ME) and were randomly assigned to either a high fat diet (HFD, 58% kcal from
fat) or a low fat diet (LFD, 11% kcal from fat) (Test Diets, St. Louis, MO). Mice were fed a HFD
or LFD for 5 months prior to being assigned to diet- and weight-matched treatment groups. In
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some studies, mice then received either MnTBAP (10 mg/kg) or vehicle (2% bicarbonate) by
daily intraperitoneal injection for five weeks while being maintained on their respective diets.
This dose of MnTBAP has been used previously in vivo [8]. To test the hypothesis that
MnTBAP action is dependent on HO-1, an identical study design was used, but during the 5
week intervention period HFDmice were treated with or without MnTBAP in the presence or
absence of a potent HO-1 inhibitor, tin mesoporphyrin (SnMP, 20 mg/kg). This dose of SnMP
has been shown to abolish HO-1 activity in tissues from mice [19]. Animal studies were con-
ducted in accordance with the National Research Council's Guide for Care and Use of Labora-
tory Animals (Institute of Laboratory Animal Resources, Commission on Life Sciences, 2011).
All experimental protocols were approved by the Skidmore College Institutional Animal Care
and Use Committee.
Insulin-Assisted Glucose Tolerance Test
Following an overnight fast, HFD-fed mice were subjected to an insulin-assisted glucose toler-
ance (IAGT) test that involves a simultaneous intraperitoneal injection of glucose (2.0 g/Kg
body weight) and insulin (2.0 U/Kg body weight). The IAGT test allows for the assessment of
blood glucose over a wider physiological range and avoids the severe hypoglycemia that occurs
during insulin tolerance tests where only insulin is injected [24]. A handheld glucometer was
used to measure blood glucose collected via the tail vein at 0, 20, 40, and 60 min following the
injection.
Caloric Intake
Caloric intake was assessed by giving mice a known amount of chow for a given period of time
(3–10 days). Remaining chow was weighed and subtracted from the initial amount of chow,
multiplied by the kcal/g for each diet, and expressed as kcal/day.
Energy Expenditure
To assess energy expenditure, mice from the LFD-Vehicle, HFD-Vehicle, and HFD-MnTBAP
groups were single-housed in Oxymax system metabolic cages (Columbus Instruments,
Columbus, OH). After 8 h to allow for adaptation to the metabolic cages, O2 consumption and
CO2 production were measured for 24 h. During this time mice had free access to water and
food. All measurements were collected at room temperature. Energy expenditure during the
light and dark cycles were calculated using the calorific value (3.815 +1.232RER)VO2 and
expressed as kcals/day.
Tissue Harvest
Mice were injected with insulin (2.0 U/Kg) and 10 minutes later were anesthetized with a 1:1:1
mixture of promace, ketamine hydrochloride, and xylazine by intraperitoneal injection (1.5
ml/Kg). Approximately 15 minutes following the injection of insulin, epididymal white adipose
tissue (EWAT), subcutaneous white adipose tissue (SWAT), and quadriceps (QUAD) muscles
were rapidly dissected, weighed, frozen in liquid nitrogen, and stored at –80°C until analysis.
Preparation of Muscle and Adipose Tissue Extracts, Electrophoretic
Analyses and Immunoblotting
Frozen QUADmuscle and EWAT were homogenized on ice in RIPA Buffer (Sigma Chemical,
Inc.) (10:1 buffer to QUADmass and 5:1 buffer to EWAT mass ratios) containing protease and
phosphatase inhibitor cocktails (Halt Protease/Halt Phosphatase, Thermo Fisher).
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Homogenates were rotated at 4°C for 1 h and centrifuged at 9,000 x g for 30 min at 4°C. The
protein concentrations of the supernatants were determined by the BCA method (Pierce, Inc),
and equal amounts of protein were subjected to SDS-PAGE along with molecular weight stan-
dards (Bio-Rad, Hercules, CA and Magic Mark, Invitrogen). Proteins were then electrophoreti-
cally transferred to Immobilon membranes and immunoblotted with phospho-specific PKB
antibodies (pThr308 PKB and pSer473 PKB). The pThr308 PKB and pSer473 PKB antibodies rec-
ognize PKB when phosphorylated on Thr308 or Ser473, two phosphorylation sites necessary for
PKB activity [25]. Light generated by the alkaline phosphatase conjugated secondary antibody
and CDP-Star reagent was detected using a digital imaging system (UVP, Upland, CA). Phos-
pho-specific immunoblots were stripped and re-probed with PKB-α or PKB-ß antibodies. To
account for gel loading differences, all immunoblots were stripped and re-probed with a
GAPDH or α-tubulin antibody. Relative signal intensities of immunoreactive bands were
determined using Total Lab software (Nonlinear, Inc., Durham, NC). All data were normalized
to the appropriate loading control and expressed as a percentage of LFD-Vehicle. The GAPDH
antibody was from Abcam (Cambridge, MA), the phospho-specific PKB and α-tubulin anti-
bodies were from Cell Signaling Technology (Beverly, MA), and the PKB-α and PKB-ß anti-
bodies were generous gifts from Dr. Morris J. Birnbaum (University of Pennsylvania).
RNA Extraction and Real Time Quantitative PCR
Total RNA was extracted from EWAT using an RNA extraction kit for lipid-rich tissues (Qia-
gen). RNA concentrations were measured using a spectrophotometer (NanoDrop, Thermo Sci-
entific). A 1 ug aliquot of total RNA was reverse transcribed using the RETROscript kit from
Ambion (Austin, TX). Quantitative polymerase chain reaction (qPCR) was performed using
cDNA and TaqMan primers for Ho-1 (Mm00516005_m1) and Gapdh (Mm99999915_g1)
using a StepOne Plus Real-Time PCR System (Applied Biosystems, Foster City, CA). Relative
quantitation of amplified cDNA targets were determined by the delta-delta cycle threshold
(ΔΔCT) method.
Statistical Analysis
A 2 x 2 (diet x treatment) analysis of variance (ANOVA) with repeated measures was used
to detect statistically significant effects of MnTBAP on body weight, caloric intake, and
blood glucose levels during the IAGT. A two-way ANOVA was used to detect statistically
significant effects of MnTBAP on EWAT mass, gene expression and area under the IAGT
curve. A one-way ANOVA was used to detect statistically significant effects of MnTBAP on
energy expenditure, oxygen consumption, and RER. A one-way ANOVA with repeated mea-
sures was used to detect statistically significant effects of HO-1 inhibition on body weight, calo-
ric intake, and IAGT, and a one-way ANOVA was used to detect statistically significant effects
of HO-1 inhibition on EWAT mass and area under the IAGT curve. Following a significant F
ratio and inspection of interactions, a priorimean comparisons were conducted using Fisher’s
least significant difference (LSD) post-hoc test. Data are expressed as means ± SEM or %
LFD-Vehicle ± SEM, and the level of statistical significance was set at p< 0.05.
Results
MnTBAP Treatment Decreases Pre-Existing Obesity by Altering Energy
Homeostasis
We first determined the effect of MnTBAP treatment on overall energy homeostasis in mice
previously fed a LFD or HFD for 6 months. As expected, body weight was higher in HFD mice
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compared to LFD mice prior to initiating MnTBAP treatment (Fig 1A and 1B). In both HFD
and LFD mice, treatment with MnTBAP resulted in significant weight loss compared to vehi-
cle-treated counterparts (Fig 1A and 1B). MnTBAP treatment significantly decreased EWAT
and SWAT (Fig 1C and 1D) mass in mice fed either a LFD or HFD. Remarkably, MnTBAP
treatment reduced EWAT and SWAT mass in HFD-fed mice to levels comparable to LFD-Ve-
hicle mice (Fig 1C and 1D). Taken together, our data indicate that MnTBAP treatment reduces
body weight and adipose tissue mass in mice with pre-existing obesity.
Next, we determined if the anti-obesity action of MnTBAP was due to changes in caloric intake
and/or energy expenditure. AlthoughMnTBAP decreased body weight and fat mass in both HFD
and LFDmice, MnTBAP treatment was associated with a significant ~10% decrease in caloric
intake in HFDmice only (Fig 2A). In addition, there was a strong correlation between the changes
in body weight and the changes in caloric intake (Fig 2B). Unlike caloric intake, changes in energy
expenditure do not appear to be increased in mice treated with MnTBAP or account for the
reduction in adiposity (Fig 3A and 3B). Furthermore, there were no differences in RER (Fig 3C)
Fig 1. MnTBAP treatment reduces body weight and adipose tissue mass in mice fed a LFD or HFD.Mice were fed a LFD or HFD for 5 months and then
treated with or without MnTBAP (10 mg/kg) daily for 5 weeks. (A) Fed-state body weights at different treatment durations. (B) Fasted body weights before
and after MnTBAP or vehicle treatments. (C) Epididymal white adipose tissue (EWAT) mass. *, Denotes statistically significant difference from respective
vehicle-treated mice. +, Denotes statistically significant difference from respective LFDmice. N = 5–6 mice per group.
doi:10.1371/journal.pone.0137388.g001
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between HFD-Vehicle and HFD-MnTBAP. Collectively, these data suggest that decreased caloric
intake contributes to MnTBAP-induced weight loss in mice with pre-existing obesity.
Fig 2. MnTBAP treatment reduces caloric intake in mice fed a HFD. (A) Caloric intake was assessed at
various time points of MnTBAP treatment in mice previously fed a LFD or HFD for 5 months. (B) Correlation
between the change in body weight and the change in caloric intake from pre-treatment to post-treatment. *,
Denotes statistically significant difference from HFD-Vehicle. +, Denotes statistically significant difference
from respective LFDmice. P-value for post-hoc analysis for LFD-Vehicle vs. HFD-Vehicle mice: Day 9,
P = 0.057; Day 17, P = 0.085. N = 6–8 mice per group.
doi:10.1371/journal.pone.0137388.g002
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MnTBAP Treatment Improves Insulin Action
In vivo insulin action was determined by conducting IAGT tests that detects diet-induced insu-
lin resistance at more physiologically-relevant blood glucose levels than insulin tolerance tests
[24]. Blood glucose values were higher at baseline and during the IAGT test in mice fed a HFD
compared to a LFD, indicating the presence of diet-induced insulin resistance (Fig 4A and 4B).
In HFD mice treated with MnTBAP, blood glucose levels were lower at baseline and during the
IAGT test compared to HFDmice treated with vehicle (Fig 4A and 4B), suggesting that
MnTBAP improves insulin resistance in mice with pre-existing diet-induced obesity. MnTBAP
did not alter blood glucose levels during the IAGT test in LFD mice (Fig 4A and 4B).
To test whether this effect was associated with enhanced insulin action in skeletal muscle
and white adipose tissue, we evaluated PKB, a key molecule in the insulin signaling cascade
that is activated by phosphorylation at Thr308 and Ser473. Following insulin stimulation, both
pThr308 and pSer473 immunoreactivity were significantly greater in muscles from HFD mice
treated with MnTBAP compared to vehicle controls (Fig 5A–5C). To determine whether the
observed increase in PKB phosphorylation was due to phosphorylation per se versus increased
content of PKB, we also determined PKB-α and β levels. PKB-α (Fig 5D) and PKB-β (Fig 5E)
immunoreactivities were higher in muscles from HFDmice treated with MnTBAP compared
to muscles from HFD mice treated with vehicle. These results indicate that MnTBAP enhances
insulin signaling in muscle by increasing the total content of PKB.
The effects of MnTBAP on PKB phosphorylation and content differed in EWAT compared
to muscle. Specifically, in EWAT of HFDmice, MnTBAP treatment increased the phosphory-
lation of Thr308 on PKB compared to vehicle-treated controls (Fig 6B). This effect was not
Fig 3. The effects of a HFD andMnTBAP treatment on energy expenditure, oxygen consumption, and
RER in mice. Indirect calorimetry using open circuit spirometry was conducted for 24 hours 3 weeks into the
MnTBAP treatment course for the assessment of energy expenditure (A), oxygen consumption (B), and RER
values (C). *, Denotes statistically significant difference from the all other groups respective of light/dark
cycle. N = 6 mice per group.
doi:10.1371/journal.pone.0137388.g003
Fig 4. MnTBAP treatment improves insulin-assisted glucose tolerance (IAGT) in mice fed a HFD.Mice were simultaneously injected with 2.0 U/Kg
insulin and 2.0 g/Kg glucose and blood glucose values were assessed at baseline and 20, 40, and 60 min following the injection (Panels A) and the area
under the IAGT curve was calculated (Panels B). *, Denotes statistically significant difference from HFD-Vehicle. +, Denotes statistically significant difference
from LFD-Vehicle mice. N = 7–14 mice per group.
doi:10.1371/journal.pone.0137388.g004
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observed for the Ser473 site on PKB (Fig 6C). Further, the content of PKB-α and β isoforms in
EWAT was not altered by MnTBAP treatment (Fig 6D and 6E). These results in EWAT sug-
gest that MnTBAP treatment improves diet-induced insulin resistance, in part, by increasing
insulin-stimulated phosphorylation of PKB on Thr308. Further, these data suggest that the
effects of MnTBAP on insulin action are tissue-specific.
MnTBAP Treatment Increases Adipose Tissue Ho-1 Gene Expression
HO-1 is an enzyme induced by metalloporphyrin molecules that has been shown to reduce adi-
posity and insulin resistance [16–19]. Further, previous studies have shown that cobalt metallo-
porphyrins can decrease obesity in an HO-1-dependent manner [16,18–23]. Therefore, we
hypothesized that the anti-obesity and insulin-sensitizing properties of MnTBAP are mediated
by HO-1. To investigate this, we first tested whether MnTBAP treatment increased HO-1
mRNA levels in EWAT and SWAT from mice fed a HFD or LFD. As expected, mice that
received MnTBAP had elevated Ho-1 levels in EWAT (Fig 7A: MnTBAP main effect,
P = 0.075) and SWAT (Fig 7B, MnTBAP main effect, P = 0.01, post-hoc P = 0.01) compared to
adipose tissue from mice that received vehicle. These results suggest that MnTBAP increases
HO-1 expression in adipose.
SnMP Does Not Block MnTBAP-Induced Changes in Adiposity, Caloric
Intake, and Insulin Action
To further address the hypothesis that HO-1 mediates the anti-obesity and insulin sensitizing
actions of MnTBAP, we next tested whether blockade of HO-1 activity with tin mesoporphyrin
(SnMP) (17), a potent HO-1 inhibitor, would prevent the ability of MnTBAP to limit obesity
and improve insulin resistance. HFD-fed mice that received both MnTBAP and SnMP experi-
enced similar decreases in bodyweight, EWAT mass, and caloric intake compared to HFD-fed
mice that received only MnTBAP (Fig 8A–8C). HFD-fed mice treated with both MnTBAP and
SnMP exhibited further enhancement of insulin sensitivity compared to HFD-fed mice that
received only MnTBAP (Fig 9A and 9B). These data suggest that MnTBAP limits obesity or
ameliorates insulin resistance in an HO-1 independent manner.
Discussion
To date, there is conflicting evidence regarding the effect of MnTBAP on adiposity and in vivo
insulin action [8,15], and it remains unknown whether MnTBAP can ameliorate pre-existing
obesity and insulin resistance by altering energy homeostasis. Further, the mechanisms by
which MnTBAP improves metabolic dysfunction are poorly understood. The present study
demonstrates that MnTBAP treatment markedly decreases pre-existing obesity and insulin
resistance by decreasing caloric intake. MnTBAP also improves insulin action by increasing
the phosphorylation and total content of PKB, a signaling molecule that is critical for insulin-
stimulated glucose transport [26]. Although MnTBAP treatment increasedHO-1 expression in
adipose tissue, this response does not appear to mediate the effects of MnTBAP on body
weight, adiposity, caloric intake or insulin action.
Fig 5. MnTBAP treatment increase insulin-stimulated PKB phosphorylation and content in muscles frommice fed a HFD.Mice were fed a LFD or
HFD for 5 months and then treated with or without MnTBAP (10 mg/kg) daily for 5 weeks. At 15 min following an intraperitoneal injection of insulin (2 U/Kg),
quadriceps muscles were excised and rapidly frozen in liquid nitrogen for subsequent Western blot analyses. (A) Representative PKB immunoblots for
pThr308 and pSer473 PKB as well as total PKB-α and PKB-β isoforms. GAPDHwas used as a loading control. Quantification of (B) pThr308 PKB, (C) pSer308
PKB, (D) PKB-α and (E) PKB-β content, each normalized to GAPDH. *, Denotes statistically significant difference from HFD-Vehicle. N = 5–6 mice per
group.
doi:10.1371/journal.pone.0137388.g005
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Pires et al. [15] recently demonstrated that MnTBAP lowered ROS in adipose tissue and
prevented weight gain during short-term HFD feeding without changes in energy expenditure
or caloric intake. The present study expands the findings of Pires et al. [15] by showing that
MnTBAP reduces adiposity in mice with pre-existing diet-induced obesity. Unlike Pires et al.
[15] we observed that MnTBAP significantly decreases caloric intake and provide evidence
suggesting that decreased caloric intake may explain approximately 46% of MnTBAP-induced
weight loss (R = 0.68, R2 = 0.46, Fig 3). These data led us to conclude that other mechanisms
also likely contribute to MnTBAP-induced weight loss. Although MnTBAP treatment was not
associated with increased energy expenditure, we found that MnTBAP increased expression of
the antioxidant-responsive geneHO-1 in adipose tissue (Fig 7), which has been previously
been shown to limit obesity and insulin resistance [16,19,21]. Previous studies have shown that
some metalloporphyrins can induce HO-1 expression and promote weight loss and that phar-
macologic treatment with the potent HO-1 inhibitor SnMP blocks this weight loss effect
[16,18–23]. In one study the beneficial metabolic effects of metalloporphyrin-induced HO-1, at
least in the liver, were shown to be mediated by sirtuin-1 (SIRT1), a deacetylase that has impor-
tant roles in metabolism [27,28]. We therefore hypothesized that the beneficial metabolic
effects of treating mice with MnTBAP, a metalloporphyrin, are mediated by HO-1. However,
surprisingly, we observed that blockade of HO-1 activity with SnMP did not affect the ability of
MnTBAP to decrease body weight, adiposity or caloric intake or to enhance insulin action.
Future studies will be required to decipher the mechanism responsible for MnTBAP-induced
reductions in caloric intake.
The ability of MnTBAP to enhance insulin action in mice with pre-existing diet-induced
obesity in our studies is consistent with prior work indicating that MnTBAP improves insulin
action in genetically obese ob/ob mice [8]. In contrast, Pires et al. observed no changes in
Fig 6. MnTBAP treatment alters insulin-stimulated PKB phosphorylation but not content in EWAT frommice fed a HFD.Mice were fed a LFD or HFD
for 5 months and then treated with or without MnTBAP (10 mg/kg) daily for 5 weeks. At 15 min following an intraperitoneal injection of insulin (2 U/Kg), EWAT
was excised and rapidly frozen in liquid nitrogen for subsequent Western blot experiments. (A) Representative PKB immunoblots for pThr308 and pSer473
PKB as well as total PKB-α and PKB-β isoforms. α-tubulin was used as a loading control. Quantification of (B) pThr308 PKB, (C) pSer308 PKB, (D) PKB-α and
(E) PKB-β content, each normalized to α-tubulin. *, Denotes statistically significant difference from HFD-Vehicle. +, Denotes statistically significant difference
from LFD-MnTBAP. N = 5–6 mice per group.
doi:10.1371/journal.pone.0137388.g006
Fig 7. MnTBAP treatment increasesHo-1mRNA levels in adipose tissue frommice fed a HFD. The mRNA levels for Ho-1 from EWAT (A) and SWAT
(B) of mice fed a LFD or HFD and treated with MnTBAP or vehicle. +, Denotes statistically significant difference from LFD-Vehicle. *, Denotes statistically
significant difference from HFD-Vehicle.
doi:10.1371/journal.pone.0137388.g007
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insulin action following MnTBAP treatment in mice fed a HFD for 5 weeks [15], a discrepancy
that may be related to the different mechanisms of insulin resistance that occur in acute versus
chronic HFD feeding [29]. In our studies, the MnTBAP-induced improvements in insulin
action is likely partially explained by the substantial reduction in adiposity observed following
MnTBAP treatment. It is well-established that weight loss produced by decreasing caloric
intake improves insulin action, and we demonstrate that MnTBAP treatment reduced caloric
intake and improved insulin action in mice fed a HFD but not in mice fed a LFD. Although the
reduction in caloric intake likely contributes to increased insulin action in mice treated with
MnTBAP, we show that MnTBAP treatment significantly increases PKB-α and PKB-β content
in skeletal muscle, resulting in greater insulin-stimulated phosphorylation of PKB. This effect
may be independent of caloric intake because previous studies have demonstrated that caloric
restriction does not affect total PKB content [30,31]. In addition to the increase in PKB content
in skeletal muscle, we demonstrated an increase in PKB phosphorylation on Thr308 in EWAT
without changes in the total abundance of the protein in HFD mice treated with MnTBAP.
These results in EWAT are likely a consequence of reduced caloric intake and the subsequent
loss of adiposity [30,31]. Taken together, these data suggest that MnTBAP has tissue specific
effects on PKB signaling pathways in skeletal muscle and white adipose tissue. The mechanism
by which MnTBAP increases the total content of PKB specifically in skeletal muscle is unclear
and warrants further study.
Fig 8. The HO-1 inhibitor SnMP does not block MnTBAP’s ability to reduce body weight, adipose tissue mass, and caloric intake in mice fed HFD.
Mice were fed a LFD or HFD for 5 months and then treated with MnTBAP (10 mg/kg) alone or in combination with SnMP (20 mg/Kg) daily for 5 weeks. (A)
Fed-state body weights at different treatment durations. (B) Epididymal white adipose tissue (EWAT) mass. (C) Caloric intake was assessed at various time
points of MnTBAP or MnTBAP+SnMP treatment in mice previously fed a LFD or HFD for 5 months. *, Denotes statistically significant difference from LFD
vehicle-treated mice. +, Denotes statistically significant difference from respective LFDmice. N = 5–6 mice per group.
doi:10.1371/journal.pone.0137388.g008
Fig 9. SnMP improves MnTBAP’s ability to reduce blood glucose levels during IAGT tests.Mice were fed a LFD or HFD for 5 months and then treated
with MnTBAP (10 mg/kg) alone or in combination with SnMP (20 mg/Kg) daily for 5 weeks. Mice were simultaneously injected with 2.0 U/Kg insulin and 2.0 g/
Kg glucose and blood glucose values were assessed at baseline and 20, 40, and 60 min following the injection (Panels A) and the area under the IAGT curve
was calculated (Panels B). *, Denotes statistically significant difference from HFD-Vehicle. +, Denotes statistically significant difference from LFD-Vehicle
mice. #, Denotes statistically significant difference from HFD-MnTBAPmice. N = 5 mice per group.
doi:10.1371/journal.pone.0137388.g009
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Conclusions
In summary, we have shown that treating mice with MnTBAP ameliorates diet-induced obesity
and improves in vivo insulin action. Almost 50% of the weight loss effect of MnTBAP is due to
decreased caloric intake and, unlike other metalloporphyrins, appears to be independent of
HO-1. Further, the decrease in adiposity following MnTBAP treatment appears to contribute
to enhanced insulin sensitivity, an effect that may mediated by tissue-specific changes in PKB
content and phosphorylation. Overall, these data demonstrate that MnTBAP promotes weight
loss and enhances insulin action by reducing caloric intake and increasing PKB activity. In con-
clusion, our results indicate that MnTBAP and possibly other SOD mimetics not only offer a
new treatment strategy for obesity and insulin resistance, but may also prove effective against
muscle wasting conditions where PKB activity is impaired.
Obesity and insulin resistance have both been associated with the over-production of ROS
and oxidative stress [4]. This association led to investigations that demonstrated improved
insulin action by enhancing the antioxidant defense system [5–8]. Although antioxidants can
reduce oxidative stress and improve insulin action [5,6,8], this effect was thought to be inde-
pendent of changes in adiposity until Pires et al. [15] recently demonstrated that MnTBAP
reduced ROS and prevented weight gain during a short-term HFD regimen in lean mice. The
present study expands the work of Pires et al [15] by showing MnTBAP reverses pre-existing
obesity following long-term HFD feeding. Taken together, Pires et al and the present study
establish MnTBAP and possibly other SODmimetics as a new avenue for the treatment of
obesity.
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